Increased cancer incidence after radioiodine treatment for hyperthyroidism.

Background: Concerns remain about risk of cancer after radioactive iodine (RAI) treatment for hyperthyroidism, especially in organs that concentrate iodine. The objective was to assess the long-term cancer risk from RAI treatment for hyperthyroidism.

Methods: A total of 2793 hyperthyroid patients treated with RAI at Tampere University Hospital between 1965 and 2002, and 2793 age- and sex-matched reference subjects were followed for an average of 10 years through the Finnish Cancer Registry.

Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism.

Context: Patients treated with radioiodine (RAI) for hyperthyroidism have been reported to be at increased risk for death. It is not clear whether the increased mortality is due to hyperthyroidism itself or the effect of RAI.

Objective: Our objective was to compare the mortality of hyperthyroid patients treated with RAI with that of an age- and gender-matched reference population.

Long-term follow-up study of radioiodine treatment of hyperthyroidism.

Objective: To determine the cumulative incidence of hypothyroidism during long-term follow-up in patients treated for hyperthyroidism by radioactive iodine (131)I (RAI) therapy, the significance of clinical factors in predicting the development of hypothyroidism, and the outcome after a fixed 7 mCi (259 MBq) dose of RAI.

Design: Prospective cohort study of patients treated for hyperthyroidism by RAI.

Patients And Measurements: Since 1965, details on 2043 patients treated by RAI therapy in Tampere University Hospital were entered into a computerized register.